Two years of DAA therapies for hepatitis C in Australia: Where are we now?


Since direct-acting antivirals (DAAs) became universally available in Australia on 1 March, 2016, they have dramatically reshaped the treatment landscape for people living with the hepatitis C virus (HCV). With the promise of greater than 95 per cent cure rates and minimal side-effects, the new regimens involve just a once-daily oral tablet.

To mark the second anniversary of the Australian federal government’s world-leading decision to subsidise DAAs for all, this seminar will feature updates and insights from four leading HCV experts.

Greg Dore will present an epidemiological overview on the impact of DAA treatment thus far; Stuart Loveday will discuss the advocacy efforts still required if we are to achieve ‘elimination’; Annie Madden will provide a community perspective on the impacts of DAAs; and Carla Treloar will offer us some insights from the world of social research. A Q&A with the panel will follow.

Who:    Professor Greg Dore (Program Head, The Kirby Institute); Stuart Loveday (CEO, Hepatitis NSW); Annie Madden (PhD Candidate, CSRH); Professor Carla Treloar (Director, CSRH and SPRC)

Organisational units